Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. HOOD
9. MU
10. IBM

Go back to Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)
Momenta Phamaceuticals, Inc. (NASDAQ: MNTA) Delayed: 52.48 --0 (-0%)
Previous Close $52.48    52 Week High $18.32 
Open $39.17    52 Week Low $7.86 
Day High $52.48    P/E N/A 
Day Low $52.48    EPS $-2.13 
Volume 147,551       

Mylan Inc. (NASDAQ: MYL) Delayed: 15.86 --0 (-0%)
Previous Close $15.86    52 Week High $55.51 
Open $10.56    52 Week Low $33.60 
Day High $15.86    P/E 10.43 
Day Low $15.86    EPS $1.52 
Volume 45,581       

Mylan Inc. (NASDAQ: MYL) Delayed: 15.86 --0 (-0%)
Previous Close $15.86    52 Week High $55.51 
Open $10.56    52 Week Low $33.60 
Day High $15.86    P/E 10.43 
Day Low $15.86    EPS $1.52 
Volume 45,581